Plain-English translation of NCT07243015 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This research is developing a blood test that looks for tiny traces of gastric cancer cells in your bloodstream after surgery. The test analyzes special molecules called exosomal microRNAs, which are released by cancer cells and can be detected in blood samples. By identifying these traces early, doctors hope to predict who might develop cancer recurrence and provide the right follow-up care at the right time.
After gastric cancer surgery, some patients develop cancer that returns or spreads, even though scans show no signs of disease. This trial exists because current imaging tests often miss these early warning signs, and doctors need a better way to identify patients at high risk so they can offer timely treatment to prevent recurrence.
You likely qualify if…
You likely don't qualify if…
If you enroll, researchers will use blood samples that were already collected before and after your gastric cancer surgery—no additional needle sticks required. Your medical records will be reviewed to track whether your cancer has recurred. The study has three phases: first, researchers will identify which blood markers best predict recurrence; then they'll test these markers in a larger group; and finally, they'll validate the test's accuracy in an independent patient group.
AI-generated summary from trial data · Jul 11, 2026 · Not medical advice
United States
Sponsor
City of Hope Medical Center
Enrollment target
~500 participants
Started
January 2025
Primary completion
June 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ajay Goel, PhD
City of Hope Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.